Announcement
10.11.2011

The Q3 interim report for NeuroSearch A/S (NEUR) will be released on 17
November 2011.

NeuroSearch will host a conference call on the same day at 9.30 am CET (8.30 pm
UK time, 3.30 am New York time) during which the Q3 report will be presented.
Participating in the call will be CEO Patrik Dahlen and EVP & CFO René
Schneider.

The conference call will be conducted in English and the dial-in numbers are:

UK and international: +44 207 509 5139
The US: +1 718 354 1226
Denmark +45 3271 4767

Listening to the teleconference is also possible via the company's website.

The corresponding presentation will be available at the company's website at
the time of the teleconference.

Contact person
René Schneider, EVP & CFO, telephone: +45 4460 8700


About NeuroSearch
NeuroSearch is a European-based biopharmaceutical company listed on NASDAQ OMX
Copenhagen A/S (NEUR) and specialising in central nervous system (CNS)
disorders. The vision is to develop NeuroSearch into a profitable specialty
pharmaceutical company. The strategy is primarily to complete the development
and subsequently to market Huntexil® (pridopidine), a unique drug in clinical
Phase III for the treatment of the motor symptoms of Huntington's disease.
NeuroSearch also has a portfolio of other assets for outlicensing or
divestment. This includes tesofensine which has shown outstanding efficacy in
the treatment of obesity, the Integrative Screening Process (ISP), which is a
proprietary systems biology approach, as well as a broad range of ion channel
technologies and patented compounds identified as ion channel modulators.

Fonds.26-11 - Release date for Q3 report - uk.pdf